Chounta, Vasiliki http://orcid.org/0000-0002-3059-3324
Overton, Edgar T.
Mills, Anthony
Swindells, Susan
Benn, Paul D.
Vanveggel, Simon
van Solingen-Ristea, Rodica
Wang, Yuanyuan
Hudson, Krischan J.
Shaefer, Mark S.
Margolis, David A.
Smith, Kimberly Y.
Spreen, William R.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)
https://doi.org/10.1007/s40271-021-00524-0
Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection
https://doi.org/10.1186/s12879-022-07243-3
Funding for this research was provided by:
ViiV Healthcare
Janssen
Article History
Accepted: 28 April 2021
First Online: 31 May 2021
Declarations
:
: ATLAS-2M is funded by ViiV Healthcare and Janssen. Open-access was funded by ViiV Healthcare.
: VC, PDB, KYS, and WRS are employees of ViiV Healthcare and stockholders of GlaxoSmithKline. ETO has received research support to his institution during the conduct of this study and served as a consultant for Gilead, Merck, Thera Technologies, and ViiV Healthcare, outside of the submitted work. AM has received research funding and consulting fees from ViiV Healthcare, Gilead, Janssen, and Merck as well as consulting fees from Shionogi, all outside the submitted work. SS reports grants from ViiV Healthcare during the conduct of the study. SV and RVS are employees and stockholders of Janssen, Pharmaceutical Companies of Johnson & Johnson. YW is an employee and stockholder of GlaxoSmithKline. KJH was an employee of ViiV Healthcare and stockholder of GlaxoSmithKline during the conduct of the study and is now an employee of Horizon Therapeutics. MSS was an employee of ViiV Healthcare and stockholder of GlaxoSmithKline during the conduct of the study and is now an employee of Hengrui USA. DAM was an employee of ViiV Healthcare and stockholder of GlaxoSmithKline during the conduct of the study and is now an employee of Brii Biosciences.
: ATLAS-2M was conducted in accordance with the principles founded in the Declaration of Helsinki and with Good Clinical Practice. The study protocol was approved by an institutional review board or ethics committee.
: All participants provided written informed consent.
: All participants provided written informed consent.
: Data sharing requests will be considered upon written request to the corresponding author. Deidentified participant data or other prespecified data will be available subject to a written proposal and a signed data sharing agreement.
: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
: ETO, AM, and SS participated in the collection and interpretation of the data. VC, PDB, SV, RVS, YW, KJH, MSS, DAM, KYS, and WRS were responsible for the development, conception, and data analysis of the study. All authors contributed to the review and development of the manuscript.